Get the Stockscreener App
165.30
1.31%
1.76
Insmed Inc stock is traded at $165.30, with a volume of 532.47K.
It is up +1.31% in the last 24 hours and up +14.46% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$163.54
Open:
$163.95
24h Volume:
532.47K
Relative Volume:
0.22
Market Cap:
$34.95B
Revenue:
$398.11M
Net Income/Loss:
$-1.03B
P/E Ratio:
-28.98
EPS:
-5.7032
Net Cash Flow:
$-868.57M
1W Performance:
+0.78%
1M Performance:
+14.46%
6M Performance:
+136.00%
1Y Performance:
+116.14%
1-Day Range:
$163.29
$166.40
1-Week Range:
$161.31
$166.44
52-Week Range:
$60.40
$166.44
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
165.35 | 34.11B | 398.11M | -1.03B | -868.57M | -5.7032 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.83 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
485.43 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
582.87 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
832.36 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.26 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Is a relief rally coming for Insmed Incorporated holdersJuly 2025 News Drivers & High Conviction Buy Zone Picks - newser.com
What dividend safety score for Insmed Incorporated stockPortfolio Value Summary & High Conviction Investment Ideas - newser.com
Does Insmed Incorporated (INSM) Have a Promising Pipeline? - Yahoo Finance
Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025 - MarketScreener
Q3 2025 Results on Oct. 30 — Insmed Schedules Investor Call; Live Webcast & Replay - Stock Titan
What moving averages say about Insmed IncorporatedMarket Volume Report & Long-Term Investment Growth Plans - newser.com
Biotech Fund Beating 92% of Peers Sees More M&A Deals to Come - Bloomberg.com
UBS Maintains Insmed (INSM) Buy Recommendation - Nasdaq
Can Insmed Incorporated hit a new high this monthMarket Performance Summary & Daily Entry Point Alerts - newser.com
UBS Raises Price Target for Insmed (INSM) Following Consistent " - GuruFocus
Insmed stock price target raised to $194 from $140 at UBS on new indications - Investing.com Canada
How Insmed Incorporated stock reacts to Fed rate cutsJuly 2025 Intraday Action & Growth Focused Entry Point Reports - newser.com
UBS Adjusts Insmed Price Target to $194 From $140, Maintains Buy Rating - MarketScreener
Key metrics from Insmed Incorporated’s quarterly dataJuly 2025 Weekly Recap & Free Safe Entry Trade Signal Reports - newser.com
Insmed Incorporated stock prediction for this weekPortfolio Risk Summary & Growth Focused Entry Point Reports - newser.com
Can Insmed Incorporated stock maintain operating marginsJuly 2025 Reactions & High Accuracy Trade Signal Alerts - newser.com
What institutional flow reveals about Insmed IncorporatedJuly 2025 PreEarnings & Intraday High Probability Setup Alerts - newser.com
Is Insmed Incorporated trending in predictive chart modelsPortfolio Performance Report & High Return Trade Opportunity Guides - newser.com
What indicators show strength in Insmed IncorporatedPortfolio Gains Summary & Real-Time Market Trend Scan - newser.com
How to build a custom watchlist for Insmed IncorporatedPortfolio Risk Summary & Short-Term Swing Trade Alerts - newser.com
Real time alert setup for Insmed Incorporated performance2025 Key Lessons & Weekly Top Gainers Alerts - newser.com
Reversal indicators forming on Insmed Incorporated stockJuly 2025 Drop Watch & Fast Entry High Yield Stock Tips - newser.com
How Insmed Incorporated (IM8N) stock performs during market turbulenceQuarterly Earnings Report & Safe Capital Growth Stock Tips - newser.com
Why Biotech’s Rally Can Last This Time - The Wall Street Journal
Insmed Incorporated (INSM) Stock Analysis: Biotechnology Growth with a 3.28% Potential Upside - DirectorsTalk Interviews
Maryland State Retirement & Pension System Invests $873,000 in Insmed, Inc. $INSM - MarketBeat
Aberdeen Group plc Decreases Stock Position in Insmed, Inc. $INSM - MarketBeat
Oak Ridge Investments LLC Sells 7,757 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed Insiders Sold US$36m Of Shares Suggesting Hesitancy - Yahoo Finance
Insmed, Inc. $INSM Holdings Raised by KLP Kapitalforvaltning AS - MarketBeat
How buyback programs support Insmed Incorporated (IM8N) stockMarket Activity Recap & Stepwise Entry and Exit Trade Signals - newser.com
Real time breakdown of Insmed Incorporated stock performanceJuly 2025 Market Mood & High Yield Stock Recommendations - newser.com
What does recent volatility data suggest for Insmed Incorporated2025 Price Targets & Reliable Breakout Stock Forecasts - newser.com
Insmed, Inc. Hits New 52-Week High of $163.22, Up 170% Yearly - Markets Mojo
Insmed stock hits 52-week high at 164.04 USD - Investing.com India
Insmed stock hits 52-week high at 164.04 USD By Investing.com - Investing.com Australia
How to interpret RSI for Insmed Incorporated stock2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Insmed (NASDAQ:INSM) - MarketBeat
Insmed, Inc. (NASDAQ:INSM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Insmed, Inc. Hits New 52-Week High of $160.62, Up 164% Yearly - Markets Mojo
Insmed, Inc. Hits New 52-Week High of $162.44, Up 171% Year-Over-Year - Markets Mojo
Pulmonary Arterial Hypertension Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma - The Globe and Mail
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schaeffer Orlov S Nicole | Chief People Strategy Officer |
Sep 12 '25 |
Sale |
145.45 |
76,520 |
11,129,927 |
36,461 |
| SHAROKY MELVIN MD | Director |
Sep 12 '25 |
Sale |
145.39 |
10,000 |
1,453,900 |
262,675 |
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):